← Leaderboards
Wantong Yao
University Of Tx Md Anderson Can Ctr
$2,140,159
Attributed
$2,140,159
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $634.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,140,159 · 2
By mechanism
R37$1,736,422 · 1
R21$403,737 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ronald Anthony Depinho$97,148,322
- Huamin Wang$4,120,166
- Anil K Sood$29,572,737
- Prasenjit Dey$3,083,364
- Y. Alan Wang$3,748,710
Others in their field
Other Rising Stars on “Membrane”
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Sabrina Paganoni · Massachusetts General Hospital$9,298,517
- Suma Babu · Massachusetts General Hospital$9,298,517
- Alexander Kolykhalov · Emory University$8,116,465
- Lisa Wagar · University Of California-Irvine$7,863,777
- Elizabeth Norton · Tulane University Of Louisiana$4,695,387
Research focus
MembraneMutateKras OncogenesisMediatingMonoclonal AntibodiesMutantGenetically Engineered MouseKras2 GeneDependenceMalignant NeoplasmsAreaBiologyBypassAutomobile DrivingClinical TrialsCancer TherapyInhibitorInnovationAntitumor EffectColorectal CancerMaintenanceMalignant Neoplasm Of PancreasCell SurvivalMutation
Grant awards (6)
Targeting Acquired Resistance in KRAS Driven Cancers$437,978
R37 · FY2025 · CA · contact PI
A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy$189,338
R21 · FY2025 · CA · contact PI
Targeting Acquired Resistance in KRAS Driven Cancers$420,385
R37 · FY2024 · CA · contact PI
A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy$214,399
R21 · FY2024 · CA · contact PI
Targeting Acquired Resistance in KRAS Driven Cancers$434,594
R37 · FY2023 · CA · contact PI
Targeting Acquired Resistance in KRAS Driven Cancers$443,465
R37 · FY2022 · CA · contact PI